14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PHIO vs CNSY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Phio Pharmaceuticals Corp. (PHIO) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHIO carries a Unified Composite Score of 42.8/100 (HOLD) at $0.74 (0.3x Forward P/E, 0.0% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. PHIO 42.8/100 HOLD), PHIO captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
Technical & Structure Timing Caution: PHIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PHIO vs CNSY. Trailing 12-month operating profitability (PHIO 0.0% vs CNSY N/A) and valuation multiples (PHIO 0.3x vs CNSY N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PHIO vs CNSY Key Questions & Quantitative Answers
As of Nov 16, 2026, Phio Pharmaceuticals Corp. (PHIO) is the stronger overall head-to-head candidate over CNSY (CNSY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PHIO carries a Unified Composite Score of 42.8/100 (HOLD) at $0.74 (0.3x Forward P/E, 0.0% operating margin), whereas CNSY carries 47.6/100 (HOLD) at $0.72 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While CNSY currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. PHIO 42.8/100 HOLD), PHIO captures the overall institutional head-to-head verdict (8–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: PHIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.0); meanwhile CNSY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PHIO leads the Growth & Scale pillar: PHIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CNSY at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PHIO generates N/A in USD-normalized revenue versus N/A for CNSY. In operating R&D and SG&A reinvestment, PHIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CNSY.
PHIO screens cheaper on headline valuation multiples. PHIO trades at 0.3x Forward P/E, 0.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CNSY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PHIO (-113.7% ROE) versus CNSY (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, PHIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 54% Vol realized risk). By comparison, CNSY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.54β · 228% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.